Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
DiaMedica said it plans to launch the trial later in 2026
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Subscribe To Our Newsletter & Stay Updated
